Tandem Diabetes Care, Inc. (TNDM) Dividend History

Company News

• Infusion Devices Market to Reach US$ 23.08 Billion by 2031, Driven by Rising Prevalence of Infectious Diseases

  The global infusion devices market is expected to grow significantly due to the increasing prevalence of cancer and strategic initiatives by market players, reaching $23.08 billion by 2031.

  GlobeNewswire Inc.

  Featured Companies: BAX BDX ICUI MDT
• Insulin Pump Market Valuation to Jump to Reach US$ 25.40 Billion by 2033 | India and China Offering Lucrative Growth Opportunities Says Astute Analytica

  The global insulin pump market is projected to reach $25.40 billion by 2033, driven by the increasing prevalence of diabetes and advancements in pump technology. India and China are emerging as key growth markets, with factors like government initiatives and rising awareness fueling demand. Leading players in the market include Medtronic, Tandem Diabetes Care, Insulet Corporation, and Roche Diabetes Care.

  GlobeNewswire Inc.

  Featured Companies: MDT PODD
• Why Tandem Diabetes Care Stock Thrashed the Market Today

  Tandem Diabetes Care received approval from the European Union's European Medicines Agency to use its t:slim X2 automated insulin delivery pump with Eli Lilly's Lyumjev ultra-rapid acting insulin. This is a positive development for both companies as they plan to expand the compatibility to other markets.

  The Motley Fool

  Featured Companies: LLY
• [Latest] US Diabetes Devices Market Size/Share Worth USD - GlobeNewswire

  The US diabetes devices market is expected to grow from $5.4 billion in 2023 to $19.8 billion by 2033, driven by trends in integration, user-friendly designs, and personalized medicine.

  GlobeNewswire Inc.

  Featured Companies: ABT BDX DXCM JNJ LLY MDT PODD SENS
• Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings? - Zacks Investment Research

  Boston Scientific Corporation is scheduled to report its Q2 2024 results on July 24. The company is expected to report revenue growth of around 11.7% and adjusted earnings of 58 cents per share. However, the company may face challenges from a challenging supply environment, rising costs, and healthcare staffing shortages.

  Zacks Investment Research

  Featured Companies: BSX EYE GKOS